The BioWorld Insider Podcast

Author: BioWorld

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma's dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.
Be a guest on this podcast

Language: en

Genres: Life Sciences, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Finding a better, longer-lasting fix in opioid overdose
Episode 54
Wednesday, 10 December, 2025

The opioid crisis may not be front and center anymore, but it's raging still. A major problem is that overdose-reversal drugs don't last long enough to help users who opt out of hospital treatment after they are revived. Elysium Therapeutics Inc. CEO Greg Sturmer talks with Randy Osborne about his firm's candidate for a solution to the medical and societal problem. The NIH – which has been helpful to Elysium since the company's founding – the FDA, and others are working to advance a longer-lasting reversal agent. Experiments already done with approved reversers, as well as computer modeling that's been used by regulators previously, will help in the push, Sturmer said.